A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT05141357

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05141357. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Pembrolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Pembrolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Study identification

NCT ID: NCT05141357
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: HUYABIO International, LLC.; Industry
Enrollment: 5 participants

Conditions and interventions

Conditions

Non Small Cell Lung Cancer

Interventions

HBI-8000 in combination with pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 15, 2022 (Actual)
Primary completion: Apr 19, 2023 (Actual)
Completion: Apr 19, 2023 (Actual)
Last update posted: Dec 24, 2025

2022 – 2023

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Western Regional Medical Center	Goodyear	Arizona	85338	—
CBCC Global Research, Inc at Comprehensive Blood and Cancer Center	Bakersfield	California	93309	—
Hematology Oncology Associates Of The Treasure Coast	Port Saint Lucie	Florida	34952	—
Southeastern Regional Medical Center	Newnan	Georgia	30265	—
Midewestern Regional Medical Center, LLC	Zion	Illinois	60099	—
Cotton O'Neil Clinical Research Center	Topeka	Kansas	66606	—
Frederick Health-JMSCI	Frederick	Maryland	21702	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05141357, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 24, 2025 · Synced Nov 12, 2026